New Data on Prostate-Cancer Mortality after PSA Screening

This is the authors' abstract. We don't add key points for this paper.

After 11 years of follow-up in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Schröder et al.1 report in this issue of the Journal that there has been little change in the apparent benefit of screening men for levels of prostate-specific antigen (PSA), as compared with an earlier report.2 Both studies showed a relative reduction of 21% in the rate of death from prostate cancer in the screening group, as compared with the control group. This reduction was achieved after considerable use of resources: in order to prevent one death from prostate cancer at 11 years of follow-up, . . .